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Sphingosine-1-phosphate (S1P) is a plasma lipid mediator with pleiotropic activities; it is constitutively produced in red blood 
cells and vascular endothelial cells through phosphorylation of sphingosine by one of two S1P synthesizing enzymes, sphingosine 
kinase 1 and 2 (SphK 1, 2), and exported into plasma to bind to high density lipoprotein  and albumin. Sphingosine-1-phosphate 
acts through five members of the G protein-coupled S1P receptors (S1PR1-S1PR5) to exert diverse actions, which include vascular 
maturation in embryonic stage and postnatal angiogenesis, maintenance of functional integrity of vascular endothelium, regulation 
of vascular tonus, and lymphocyte trafficking. Sphingosine-1-phosphate is unique in its ability to regulate cell migration either 
positively or negatively by acting through different receptor subtypes. S1PR1 and S1PR3 mediate chemotactic cell migration 
toward S1P via Gi/Rac pathway, whereas S1PR2 mediates S1P inhibition of chemotaxis via G12/13/Rho-dependent inhibition of 
Rac. Sphingosine-1-phosphate positively or negatively regulates tumor cell migration, invasion in Matrigel, and hematogenous 
metastasis in manners strictly dependent on S1P receptor subtypes expressed in tumor cells. S1PR1 (and S1PR3) also mediates 
activation of Gi/phosphatidylinositol 3-kinase (PI3K)/Akt and stimulation of cell proliferation/survival, whereas S1PR2 could 
mediate suppression of cell proliferation/survival through G12/13/Rho/Rho kinase/PTEN-dependent Akt inhibition. S1PR1 (and 
S1PR3) expressed in endothelial cells mediates angiogenic action of S1P by stimulating endothelial cell migration, proliferation 
and tube formation. In a mouse model of hindlimb ischemia after femoral artery resection, repeated local administration or sus-
tained delivery of S1P, or transgenic overexpression of SphK1, accelerates post-ischemic angiogenesis, through the S1P actions 
on both endothelial cells and bone marrow-derived myeloid cells (BMDCs). In tumor cells, SphK1 is upregulated especially 
in advanced stages, through mechanisms involving both activating Ras mutation and hypoxia, which leads to increased S1P 
production and also decreased cellular content of pro-apoptotic sphingolipid ceramide, a metabolic precursor of S1P. Apoptotic 
tumor cells also produce S1P through SphK2 activation, thus implicated in tumor angiogenesis by acting on endothelial cells 
through S1PR1/S1PR3, as well as tumor-infiltrating macrophages and BMDCs. Inhibition of S1PR1 function by either an anti-
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introduction
During the past two decades the existence of the novel 
intercellular signaling system has been elucidated, which 
comprises a plasma lysophospholipid mediator sphingosine-
1-phosphate (S1P) (1), its synthesizing/degrading enzymes 
(2-6), membrane S1P transporters (7,8), S1P carrier proteins 
in the plasma (9), and five members of the G protein-coupled 
S1P-specific receptor subtypes, S1PR1~S1PR5 (10-22). 
The S1P signaling system plays crucial roles in mammalian 
embryonic development (24-26) and post-natal homeostasis 
in the cardiovascular (27-36), immune (37-47) and nervous 
systems (26,48). The S1P signaling system is also implicated 
as the target of therapeutic intervention in a variety of human 
diseases. Multiple sclerosis, a debilitating autoimmune disease, 
is now treated with the S1P receptor agonist prodrug FTY720 
(49), whose phosphorylation product downregulates S1PR1 
in lymphocytes to inhibit their recirculation, thus resulting in 
lymphopenia (38,50). In addition, accumulated evidence in 
experimental animal disease models indicates that targeting 
the S1P signaling system is a promising tactic for both angio-
genic and anti-angiogenic therapies, for treating obliterative 
peripheral arterial diseases and malignant tumors, respectively 
(51-57). Before addressing this point, we will overview how 
blood vessels are generated during embryonic phase and after 
birth, and how the S1P signaling system is involved in blood 
vessel formation in physiological and pathological conditions.
VaSculoGeneSiS, anGioGeneSiS, and VaScular 
Maturation in deVeloPMent
Mammalian blood vessels are generated by two different 
mechanisms, i.e. vasculogenesis and angiogenesis, in which 
endothelial cells derived from distinct sources are involved 
(58-61). In vasculogenesis, which is a process of de novo 
blood vessel formation in the early embryonic phase, en-
dothelial progenitor cells (EPCs) or angioblasts differentiate 
from mesodermal cells, which proliferate, migrate and dif-
ferentiate to become endothelial cells that are endowed with 
cell surface adhesion molecules including PECAM (platelet 
endothelial cell adhesion molecule) and vascular endothelial 
(VE)-cadherin. Endothelial cells then form aggregates through 
the homologous cell-cell adhesion, followed by dynamic 
morphogenesis and remodeling to form a primordial tubular 
network. The endothelium in the early embryo is then des-
tined to either arterial or venous differentiation, leading to 
the formation of the dorsal aorta and cardinal vein. A part of 
arterial endothelial cells give rise to hematopoietic stem cells 
to initiate definitive hematopoiesis, whereas a part of venous 
endothelium differentiate to become lymphatic endothelial 
cells to form blind-ended lymphatic vessels (61).
Vasculogenesis is followed by angiogenesis, which takes 
place not only in embryonic period but also after birth. In 
angiogenesis, new vessels are created by sprouting of pre-
existing capillaries (61,62). In response to pro-angiogenic 
chemoattractant signals in the microenvironment, capillary 
endothelial cells are destabilized, stimulated to migrate, in-
vade through extracellular matrix (ECM) with its proteolytic 
degradation, and proliferate to form a cylindrical sprout, in 
which tip cells, a minor population of leading cells that sense 
and respond to pro-angiogenic cues, and stalk cells that trail 
the tip cells and form a cylinder structure, are distinguished. 
Sprouting new vessels get together to coalesce and undergo 
remodeling to build up microvessel networks in previously 
avascular areas (61,62). 
Newly formed blood vessels then undergo the process of 
maturation, in which endothelial tubes are covered with mu-
ral cells (pericytes and vascular smooth muscle cells), which 
stabilize and strengthen the vessels, resulting in the formation 
S1P antibody or FTY720 inhibits tumor angiogenesis and tumor growth. Differently from S1PR1, S1PR2 expressed in host cells 
mediates inhibition of tumor angiogenesis and tumor growth, through mechanisms involving the suppression of endothelial cell 
migration, proliferation and tube formation, and inhibition of BMDC recruitment to tumor stroma with suppressed expression 
of pro-angiogenic factor and matrix metalloprotease 9. These findings provide the molecular basis for S1P receptor subtype-
selective targeting strategies aiming at angiogenic therapy for occlusive peripheral arterial diseases, and anti-angiogenic and 
anti-tumor therapies against cancer. Biomed Rev 2011; 22: 15-29.
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of a mature vascular bed (61-64). This process depends upon 
the recruitment of mural cells and heterologous endothelial-
mural cell adhesion.
Angiogenic expansion, remodeling and vascular maturation 
leads to the formation of a fully functional embryonic vascular 
system. In addition, angiogenesis takes place after birth under 
both physiological and pathological conditions, which include 
wound healing, post-menstrual endometrial regeneration, 
inflammation-associated angiogenesis, post-ischemic angio-
genesis and tumor angiogenesis (61,62,65). Importantly, bone 
marrow-derived myeloid cells and macrophages play a crucial 
role in preparing angiogenic microenvironment, through the 
production of pro-angiogenic growth factors, chemokines 
and cytokines, and proteases that degrade ECM and release 
ECM-bound growth factors, and by physically interacting with 
and thereby supporting vascular sprouting. In addition, under 
certain conditions circulating EPCs derived from bone marrow 
could be incorporated into angiogenic neovessels (65-67).
Vasculogenesis and angiogenesis are controlled by mul-
tiple arrays of pro-angiogenic growth factors, chemokines, 
cytokines, guidance molecules and their receptors, ECM com-
ponents and their receptor/adhesion molecules, in a complex, 
spacio-temporally organized manner. Vascular endothelial 
growth factors (VEGFs) are the most critical driver of vas-
culogenesis and angiogenesis. Angiopoietins, ephrins and 
platelet-derived growth factors (PDGFs), and transforming 
growth factor-β (TGF-β) are required for vascular remodeling 
and maturation (58-67). In addition to these angiogenic fac-
tors, S1P is attracting increasing attention as a regulator of 
vascular formation.
tuMor anGioGeneSiS
Tumor angiogenesis plays a crucial role in tumor progression 
(68). As soon as a tumoral micronodule becomes hypoxic 
especially in the core region, the cellular level of hypoxia 
inducible factor1a (HIF1a) is upregulated, through the escape 
from von Hippel-Lindau protein-mediated proteasomal degra-
dation (69). The formation of a HIF1a-containing transcription 
factor leads to stimulation in the expression of multiple genes 
that are involved in tumor progression, which include glucose 
transporters GLUT1/3, glycolytic enzymes, VEGF and other 
pro-angiogenic factors and SphK1 (69-72). These events 
switch on tumor angiogenesis, a critical event that allows 
abundant oxygen and nutrient supply to tumor cells to let the 
previously minute tumor proceed through the next stage, i.e. 
tumor progression with a rapid growth, invasion and eventual 
metastasis, processes dependent on newly constructed tumor 
vessels (68).
In tumor angiogenesis, endothelial cells in preexisting 
blood vessels located in the vicinity of tumors are induced to 
destabilize, migrate toward a tumor, proliferate and undergo 
morphogenesis to form networks of microvessels (65). These 
processes are reminiscent of developmental angiogenesis and 
regulated by multiple pro-angiogenic growth factors includ-
ing VEGFs, angiopoietin-1, fibroblast growth factors (FGFs) 
and PDGFs, which are produced by both tumor cells and host 
stromal cells, among which are tumor-associated macrophages 
(TAMs) and other bone marrow-derived cells (BMDCs), 
which include CD11b+ myeloid cells (58,59,65-69). TAMs are 
macrophages that have undergone phenotypic change in tumor 
microenvironment from a classically activated phenotype of 
proinflammatory anti-tumor immunocompetent M1 state to an 
alternatively activated, anti-inflammatory and angiogenic M2 
state that favors tumor growth. Tumor-associated macrophages 
and BMDCs not only produce pro-angiogenic growth factors, 
tumor promoting growth factors and chemotactic factors 
that mobilizes BMDCs to tumor microenvironment, but also 
activate matrix metalloproteases (MMPs), which degrade 
ECM and liberate matrix-bound proangiogenic factors, thus 
establishing an angiogenic tumor microenvironment (69). 
The recruitment of pericytes and SMCs to the newly formed 
microvessels stabilizes them, establishing stable and abundant 
blood supply (60-64). Accumulated evidence now indicates 
that S1P is involved in tumor angiogenesis and tumor pro-
gression. 
Production and deliVery of S1P
S1P is present in the plasma at the order of 10-7 mol/L, which is 
for the most part bound to HDL and albumin (19,35,36,42,70). 
The major source of plasma S1P is red blood cells (43,71) and 
vascular endothelial cells (72), in which S1P is constitutively 
produced by SphK1 through phosphorylation of sphingosine, 
and exported by plasma membrane S1P transporters (7,8), fol-
lowed by specific binding to HDL-associated apolipoprotein 
M (and non-specific binding to albumin) in the plasma (73). 
SphK1 and the other S1P synthesizing enzyme SphK2 share 
a conserved catalytic domain but are expressed in spacio-
temporally distinct manners (74). Deletion of either SphK1 
or SphK2 is functionally fully compensated by each other, 
whereas SphK1/SphK2 double knockout (KO) mice are em-
bryonic lethal with an undetectable tissue level of S1P, indicat-
ing that S1P is produced exclusively by SphK1 and SphK2 in 
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vivo (26,75,76). In addition to erythrocytes and endothelial 
cells, activated platelets, mast cells and other types of cells 
release S1P (77). S1P thus released by blood cells and vascular 
endothelial cells activates endothelial S1PR1, the principal S1P 
receptor subtype expressed in this cell type, which mediates 
mitogenic, anti-apoptotic and chemotactic effects of S1P, as 
well as S1P-dependent suppression of vascular permeability, 
implicating critical role of S1P in maintenance of vascular 
integrity and wound healing (35,36). In addition, in various 
types of cells either of the SphKs could be stimulated to pro-
duce S1P in response to growth factors and cytokines (74). 
It is of note that in tumor cells, especially in advanced 
stages, SphK1 is upregulated through multiple mechanisms, 
which include Ras activation, deletion of p53, and hypoxia 
(69-72, 78-89). SphK1 upregulation leads to not only increased 
production of S1P, but also a reduction in cellular levels of 
pro-apoptotic ceramide and sphingosine, which are metabolic 
precursors of S1P (90-94). Upregulation of SphK1 and a re-
duction in ceramide in tumor cells are closely associated with 
their acquisition of resistance against chemotherapeutic agents 
(78,80,81,84,95).  On the other hand, SphK1 is implicated in 
upregulation of HIF1a (71,72). Thus, SphK1 and HIF1a may 
constitute a feed-forward amplification loop favoring tumor 
progression. In addition to S1P derived from hypoxic tumor 
cells through the action of SphK1, S1P is also released from 
apoptotic tumor cells, in which SphK2 is responsible for 
S1P production (96). S1P thus released from tumor cells is 
implicated in tumor angiogenesis, in which endothelial cells 
and tumor-infiltrating BMDCs and macrophages are targets 
of S1P actions (94,96-98). Indeed, S1P plays an essential role 
in inducing M2 phenotype in macrophages to render them to 
behave as TAMs, in which transcriptional upregulation of 
HIF1a under normoxia is implicated (98).
Gi-couPled cheMotactic S1Pr1/S1Pr3 Mediate a 
Pro-anGioGenic action of S1P 
Ubiquitously expressed S1P receptor subtypes, S1PR1, S1PR2 
and S1PR3 have been studied extensively. They play crucial 
roles in mediating diverse actions of S1P, which reflect recep-
tor subtype-dependent distinctive intracellular signaling and 
their cell type-specific expression patterns (Fig. 1) (12-19, 
20-23,40,99-104). Vascular endothelial and smooth muscle 
cells, as well as leukocytes of both myelocytic and lymphocytic 
lineages, are the major targets of S1P action through either of 
the three major S1P receptor subtypes. The other members, 
S1PR4 and S1PR5, are relatively restricted in their expression 
to the immune and the nervous system, respectively (22).
S1PR1 couples exclusively to Gi and activates well known 
Gi-dependent pathways, including Ras-ERK and PI3K-Akt 
pathways, which lead to stimulation of mitogenesis and 
survival (Fig. 1). S1PR1- Gi-PI3K axis also activates Rho 
family small GTPase Rac, which is essential for regulating 
actin cytoskeleton and cell migration. In addition to Ras-ERK, 
PI3K-Akt and -Rac activation, S1PR1 mediates activation of 
phospholipase C (PLC) with consequent Ca2+ mobilization 
via Gi (13-15,19-23,40,99,102-104).  
Rac activation leads to subcellular cortical actin assembly 
and focal contact to ECM, giving rise to lamellipodia or 
membrane ruffling (105) that features the leading edge of 
migrating cells toward chemotactic ligands and growth factors 
for Gi-coupled receptors and receptor tyrosine kinases. Rac 
is required for cell migration in vitro and in vivo for vascular 
formation in embryo (99,106). 
S1PR1 is expressed in a variety of cell types including 
vascular endothelial cells, leukocytes of both lymphoid and 
myeloid origins, fibroblasts and tumor cells of epithelial and 
non-epithelial origins. S1PR1 expressed in these cell types, if 
not counteracted by an opposing function mediated by S1PR2, 
mediates chemotaxis toward S1P in pertussis toxin-sensitive, 
Rac-dependent manners (24,28-31,47). 
S1PR1 expressed in lymphocytes is responsible for their 
egress from secondary lymphoid organs to lymph and then 
blood according to an increasing S1P concentration gradient 
imposed among these compartments, ensuring lymphocyte 
recirculation and immune surveillance. A Chinese medicine-
derived sphingosine mimetic FTY720 (FingolimodR) is a 
potent S1P receptor modulator prodrug with multiple ac-
tions, which after phosphorylation by SphK2 in vivo, acts 
as an agonist for S1PR1, S1PR3, S1PR4 and S1PR5 but not 
S1PR2, and also as a functional antagonist for S1PR1 because 
of inducing its downregulation (38,39,44,45,107). S1PR1 
downregulation in lymphocytes results in the failure of their 
egress from secondary lymphoid organs and, thereby, periph-
eral blood lymphopenia. FTY720 is now clinically employed 
as an immunosuppressive drug for the treatment of multiple 
sclerosis (49).
S1PR1 expressed in vascular endothelial cells, together 
with S1PR3, mediates angiogenic action of S1P, which in-
clude stimulation of endothelial cell migration, proliferation, 
survival and morphogenesis of tubular structures, which de-
pends upon reinforcement of VE-cadherin mediated adhesion 
between endothelial cells (27,32-35,104,109). Endothelial 
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Figure 1.  S1P receptor subtype-specific coupling to heterotrimeric G proteins and intracellular signaling pathways. 
S1PR1 couples exclusively to Gi to activate Ras-ERK and PI 3-kinase (PI3K)-Akt/Rac pathways, leading to stimulation of 
chemotaxis and cell proliferation. S1PR3 activates Gq-PLC-Ca2+ pathway, and Gi-Ras-ERK and -PI 3-kinase-Akt/Rac pathways. 
S1PR3- G12/13 –Rho pathway is masked and not evident unless Gi is inhibited by pertussis toxin. S1PR2 couples to G12/13 to induce 
potent Rho activation, leading to inhibition of Rac and cell migration, and also inhibition of cell proliferation via inhibition of 
Akt. S1PR1/S1PR3 expressed in endothelial cells (ECs) and bone marrow-derived myeloid cells (BMDCs) mediate angiogenic 
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S1PR1 is also required for maturation and stabilization of 
nascent microvessels, which includes recruitment of mural 
cells and their tight coverage around naked endothelial tubes, 
in which heterologous endothelial-mural cell adhesion should 
take place. Indeed, in S1PR1-null mice vasculogenesis takes 
place normally but mural cell coverage is defective, leading 
to massive hemorrhage and embryonic death at mid-gestation 
(24). This phenotype is reproduced in endothelial cell-specific 
conditional S1PR1 knockout (KO) mice, and also in SphK1/2-
double KO mice. PDGF-B null mice also show defective 
mural cell coverage and vascular maturation among other 
abnormalities. In endothelial-mural cell adhesion, endothelial 
S1PR1-Gi-PI3K-Rac signaling is required for phosphoryla-
tion of N-cadherin and N-cadherin/β-catenin/actin complex 
formation (110). 
Endothelial S1PR1-dependent cell-cell adhesion is essential 
not only for angiogenesis and vascular maturation, but also 
for maintenance of vascular integrity through suppression of 
transmural permeability and leakiness. In this procss S1PR1-
Gi-PI 3-kinase-Rac-dependent signalings are also operating, 
which include enhancement in formation of VE-cadherin-
based formation of adherens junctions (111) and also that of 
tight junctions, in which junctional adhesion molecules such 
as zona occludens (ZO) proteins are involved (27,112). 
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It is reported recently that S1PR1/3 mediate macrophage 
phenotype switching from proinflammatory (classic) to anti-
inflammatory (alternative) phenotype, leading to suppression 
of proinflammatory cytokine secretion. It is also reported that 
S1PR1/3 signaling contributes to induction of TAM phenotype 
(96).
S1PR3 resembles S1PR1 in that it activates Ras-ERK, PI 
3-kinase-Akt and -Rac via Gi, mediating mitogenic/prosurvival 
and chemotactic effects of S1P (17-23,40,99-104,113). In ad-
dition, S1PR3 couples to Gq to potently activate PLC-Ca2+ 
signaling, and to G12/13-Rho, the latter being a relatively minor 
pathway that becomes evident in pertussis toxin-treated, Gi-
inactivated condition (99,113). 
S1PR3 (and S1PR1) plays a pivotal role in S1P activa-
tion of endothelial nitric oxide synthase (eNOS), in which 
Ca2+-dependent, Akt-dependent and ERK1/2-dependent 
mechanisms are operating (103,114-117). Thus, S1P induces 
NO-dependent vascular relaxation via S1PR3 (and S1PR1) 
activation in endothelial cells. In addition, NO plays crucial 
roles in protection of endothelial function and prevention of 
atherogenesis. S1P specifically binds to M apolipoprotein in 
HDL. HDL exerts its anti-atherogenic effects not only by sub-
tracting excess cholesterol from vascular endothelium but also 
by providing endothelial S1PR1 and S1PR3 with S1P (114). 
S1PR3 expressed in vascular smooth muscle cells, on the 
other hand, mediates vascular contraction via Gq-coupled Ca2+ 
mobilization and consequent activation of myosin light chain 
kinase and protein kinase C. Relative contributions of S1PR3 
expressed in vascular endothelial vs. smooth muscle cells on 
vascular tone could depend upon vascular beds. In addition 
to mediating S1P actions on vasoconstriction or relaxation, 
S1PR3 expressed in the heart mediates negative chronotropic 
effect in a Gi-dependent manner, which is reminiscent of 
muscarinic acetylcholine receptor. S1PR3 KO mice are phe-
notypically normal (103) . 
G12/13-couPled cheMorePellant S1Pr2 MediateS an 
anti-anGioGenic action
S1PR2 is quite different from S1PR1 and S1PR3, and is the 
first G protein-coupled receptor to be identified that mediates 
inhibition of cell migration (99, 102,113,118-120). The rep-
ertoire of G protein coupling by S1PR2 overlaps with that of 
S1PR3, however, S1PR2 robustly couples to G12/13 to induce 
potent activation of RhoA (16,19-23,99,101-104,113,118-120). 
At the site downstream of G12/13-RhoA, S1PR2 potently inhib-
its chemoattractant-induced Rac activation via stimulation of 
Rac GTPase-activating protein (Rac GAP) activity to inhibit 
cell migration toward these chemoattractants (19-23,99,102-
104,118-120). Endogenous S1P2R expressed in B16 mela-
noma cells mediates inhibition of Rac, cell migration and 
invasion in Matrigel, which are abolished by S1PR2-selective 
antagonist, JTE013 (118). 
S1PR2-mediated, G12/13-coupled RhoA activation also 
leads to activation of Rho kinase or ROCK, and ROCK-
dependent activation of PTEN, with consequent reductions in 
3’-phosphorylated phosphoinositides, PIP3 and PIP2, which are 
required for Akt activation (121). Inhibition of Akt via S1PR2 
leads to inhibition, rather than stimulation, of cell proliferation 
by S1P (121-124). S1PR2 mediates relatively weak activation 
of Ras/ERK and PI3K pathways via Gi (16,20-23,99,101-
104,118), which may explain mitogenic actions of S1PR2 
under certain conditions.
S1PR2-mediated, G12/13-Rho-dependent inhibition of 
Rac and Akt underlies potent inhibitory action of S1PR2 on 
angiogenesis (123). Thus, S1PR2 expressed in murine lung 
microvascular endothelial cells (MLECs) mediates inhibition 
by S1P of their migration, proliferation, and tube formation 
in vitro, and angiogenesis in vivo in subcutaneous Matrigel 
plug assay and tumor angiogenesis. In S1PR2 KO mice tumor 
angiogenesis and tumor progression are significantly enhanced 
as compared to wild type (WT) littermates. Subcutaneous 
inoculation of tumor cells in WT mice together with MLECs 
obtained from S1PR2 KO mice markedly potentiated tumor 
angiogenesis and tumor growth as compared to tumor cell in-
oculation with WT MLECs, which implicates endothelial cell-
autonomous function of S1PR2. In addition, the recruitment 
of BMDCs to tumor stroma, the expression of proangiogenic 
factors, and MMP9 activity were all enhanced in S1PR2KO 
mice as compared to WT littermates. Bone marrow transplanta-
tion experiments using S1PR2LacZ/LacZ mice demonstrated that 
S1PR2 expressed in tumor-infiltrating BMDCs, which include 
CD11b+ cells implicated in tumor angiogenesis, play a crucial 
role in inhibiting tumor angiogenesis. Deletion of S1PR2 only 
in BMDCs significantly potentiated tumor angiogenesis and 
tumor growth in WT mice. These results indicate that S1PR2 
expressed in endothelial cells and BMDCs in concert mediate 
inhibition of tumor angiogenesis and tumor growth (123). 
Consistent with these observations, S1PR2 expressed in 
macrophages mediate S1P inhibition of their recruitment to 
inflammatory sites (123). However, S1PR2 in endothelial cells 
also mediates inflammatory effects of S1P, by upregulation of 
the proinflammatory enzyme cyclooxygenase 2 (COX2) and 
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downregulation of eNOS expression. In S1PR2 KO neonates 
that are subjected to ischemia-driven retinopathy, revascu-
larization into avascular zones of the retina were augmented, 
whereas pathologic neovascularization in the vitreous chamber 
was rather suppressed, with reductions in endothelial gaps and 
inflammatory cell infiltration (117). 
S1PR2 also mediates S1P stimulation of PLC and Ca2+ 
mobilization via Gq and G12/13, (16,125), which in some 
vascular beds results in vascular contraction, contributing to 
normal hemodynamic regulation. 
S1PR2 KO mice develop abnormalities in the inner ear, 
i.e., deafness and vestibular ataxia, in which hemodynamic 
derangement due to abnormally dilated capillaries in stria vas-
cularis is involved (126). S1PR2KO mice also show occasional 
convulsion around weaning age with abnormal electroencepha-
logram (48), and spontaneous development of diffuse large B 
cell lymphoma in adulthood (127). Molecular mechanisms for 
these phenotypes are yet to be fully understood. 
S1PR1/2 double null and S1PR1/2/3 triple null embryos 
show more severe defects in embryonic vascular formation and 
earlier death in utero, compared to S1PR1 single null embryos. 
S1PR2/3 double null embryos also show partial embryonic 
lethality and vascular abnormalities. These results indicate 
that coordinated functions of S1PR1, S1PR2 and S1PR3 are 
required for development of a fully functional vascular system 
during embryonic stage (126).
S1PR1, S1PR2 and S1PR3 are widely expressed in various 
types of cells. The overall outcome of S1P signaling in a given 
cell type largely depends upon relative expression levels of 
the S1P receptor subtypes. In addition, cross-talks between 
S1P receptor signalings and growth factor or cytokine recep-
tor signalings have been reported. For example, S1PR1 and 
VEGF receptor activation in concert stimulate angiogenesis. 
Under certain conditions S1PR3 activation leads to activation 
of TGF-β signaling pathway and fibrosis (128,129). Update 
information regarding detailed cross-talk mechanisms is avail-
able in recently published excellent reviews (22,95,130,131).
StiMulatinG S1P SiGnalinG Pathway for treatMent 
of PoSt-iScheMic anGioGeneSiS
Patients with occlusive peripheral arterial diseases suffer from 
limb ischemia, seeking for effective angiogenic therapy. For 
these patients, the clinical trials of either administration of 
proangiogenic growth factors such as VEGF, FGF-2 and HGF, 
or their expression vectors, or bone marrow mononuclear cell 
implantation which supplies myeloid lineage cells that produce 
proangiogenic factors and endothelial progenitor cells, have 
been conducted (132-136). These trials demonstrated that the 
angiogenic therapy conferred some beneficial effects such as 
reduced pain and decreased need for amputation, however, the 
effects are not satisfactory and obtained only in a portion of 
patients. Some drawback has been reported in the angiogenic 
therapy: administration of VEGF causes increases in vascular 
permeability and resultant edema as a serious side effect. 
We demonstrated for the first time that S1P was effective 
in stimulating post-ischemic angiogenesis in a mouse model 
of hindlimb ischemia after unilateral femoral artery resection 
(51,52). Daily intramuscular administration of S1P dose-
dependently stimulated blood flow recovery, resulting in up 
to twice as much blood flow at 10-7 M of S1P, which was 
accompanied by 1.7-fold increase in the capillary density in 
ischemic muscle compared with vehicle control. The optimal 
S1P effects were comparable with those obtained with FGF-2. 
Differently from VEGF, S1P injections did not increase vascu-
lar permeability, which was evaluated by Miles assay. We also 
analyzed post-ischemic angiogenesis in SphK1-overexpressing 
transgenic (TG) mice. SphK1 TG mice showed 40-fold higher 
sphingosine kinase activity and 1.8-fold higher S1P content in 
skeletal muscle compared with WT mice (51). In SphK1 TG 
mice the post-ischemic blood flow recovery and angiogenesis 
were both accelerated compared with WT mice, without an 
increase in the vascular permeability. These observations sug-
gest that S1PR1/3-mediated angiogenic signals are dominant 
over anti-angiogenic signal mediated via S1PR2, and indicate 
potential therapeutic usefulness of S1P for tissue ischemia. We 
then explored the way to achieve sustained delivery of S1P, 
and found that poly(lactic-co-glycolic-acid) (PLGA)-based 
S1P-containing microparticles (PLGA-S1P) are biodegrad-
able and continuously release S1P (52). We studied the effects 
of PLGA-S1P microparticles and found that intramuscular 
injections of PLGA-S1P dose-dependently stimulated blood 
flow and increased microvessel density in C57BL/6 mice with 
injections every 3 days conferring the optimal result. In Balb/c 
mice, which show retarded blood flow recovery compared 
with C57BL/6 mice and exhibit limb necrosis with apparent 
functional dysfunction, injections of PLGA-S1P stimulated 
blood flow with alleviation of limb necrosis and dysfunction. 
PLGA-S1P microparticles did not induce edema in ischemic 
limbs but rather suppressed VEGF-induced edema. Moreover, 
we observed that PLGA-S1P promoted the coverage of ves-
sels by smooth muscle cells and pericytes, thus stabilizing 
vessels. PLGA-S1P microparticles stimulated Akt and ERK 
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with increased phosphorylation of eNOS in ischemic muscle. 
Experiments with a nitric oxide synthase (NOS) inhibitor 
showed that the stimulatory effect of PLGA-S1P on blood flow 
recovery was in part dependent on NO production. PLGA-
S1P also stimulated the expression of pro-angiogenic growth 
factors in ischemic tissues, and enhanced the recruitment of 
CD45+, CD11b+ and Gr-1+ myeloid cells, which are known to 
contribute to post-ischemic angiogenesis through production 
of pro-angiogenic growth factors (52). 
These results indicate that PLGA-based, sustained lo-
cal delivery of S1P is a promising therapeutic modality for 
stimulating post-ischemic angiogenesis. It is expected that 
S1P receptor subtype-selective agonists and antagonists could 
confer better effects in therapeutic angiogenesis.
tarGetinG the S1P SiGnalinG Pathway for 
controllinG tuMor anGioGeneSiS
Tumor angiogenesis has been the target of an anti-VEGF 
monoclonal antibody (mAb)(bevacizumab or AvastinR) (132) 
and inhibitors of receptor tyrosine kinases or multi-kinase 
inhibitors. These modalities have limitations, because of side 
effects, including perforating peptic ulcer, hypertention and 
proteinuria associated with anti-VEGF therapy, and acquisition 
by tumor cells of resistance. 
Accumulated evidence provides molecular basis for 
anti-angiogenic therapy through targeting the S1P signaling 
pathway. Anti-S1P mAb (Sphingomab) (53,54), has been de-
veloped and shown to act as a molecular sponge to efficiently 
bind S1P, preventing its binding to cell surface receptors. The 
anti-S1P mAb inhibits tumor progression in mouse xenograft 
and allograft models through inhibition of tumor angiogenesis. 
Thus, the anti-S1P mAb blocked endothelial cell migration and 
formation of tubular structures in vitro, and inhibited blood 
vessel formation induced by pro-angiogenic growth factors 
and arrested tumor-associated angiogenesis in vivo (53). The 
anti-S1P mAb also inhibited mitogenic and anti-apoptotic ef-
fects of S1P in tumor cells and their release of proangiogenic 
cytokine (53,54). Since the antibody is capable of triggering 
S1P release from erythrocytes (71), which constitute a large 
reservoir of plasma S1P, suitable antibody delivery system that 
bypass bloodstream to target primary and metastatic tumor 
tissues would improve cost performance status. 
Since S1P stimulates and inhibits tumor angiogenesis 
through S1PR1/3 and S1PR2, respectively, either S1PR1/3-
selective antagonists or S1PR2-selective agonists are expected 
to be effective in inhibiting tumor angiogenesis and tumor 
growth. At present the former strategy is under investigation 
in experimental models whereas the latter not yet available. 
As described above, downregulation of S1PR1 by FTY720-
phosphate in lymphocytes inhibits lymphocyte trafficking. 
FTY720-phosphate also induces downregulation of S1PR1 
in endothelial cells and suppresses angiogenic activity of 
S1P (50). Pretreatment of HUVECs with nanomolar concen-
trations of FTY720 or FTY720-phosphate downregulated 
S1PR1 and inhibited endothelial cell migration in response 
to subsequent S1P. FTY720 potently inhibited angiogenesis 
in a variety of in vivo models, including corneal micropocket 
assay, subcutaneously implanted chamber assay, and tumor 
angiogenesis, tumor growth and metastasis (55-57). Moreo-
ver, FTY720 at micromolar concentrations directly induced 
apoptosis of a breast cancer cell line (55). It is also reported 
in ovarian cancer cells that FTY720 induced autophagy and 
necrosis (137). These observations may be related to recently 
reported novel actions of FTY720, which include inhibition of 
SphK1 (138) and autotaxin, the latter being phospholipase D 
in the plasma responsible for production of the lipid mediator 
lysophosphatidic acid (139). Because of the fact that FTY720 
is a potent immunosuppressant, it is concerned that its clini-
cal use for cancer patients is compromised by suppression in 
anti-tumor immunity and increased risk of opportunistic infec-
tion. In addition, endothelial dysfunction with reduced eNOS 
activity and increased permeability could occur. It is reported 
that the induction of vascular leak by FTY720 is associated 
with ubiquitin-dependent degradation of endothelial S1PR1 
in mice (139). 
future PerSPectiVeS
Recently novel pharmacological S1P receptor antagonists with 
anti-angiogenic potential have been reported. These include the 
S1PR1/3 antaonist, compound 5, {sodium 4-[(4-butoxyphenyl)
thio]-2’-[{4-[(heptylthio)methyl]-2-hydroxyphenyl}(hydroxy)
methyl]biphenyl-3-sulfonate} which inhibited endothelial cell 
migration, proliferation and tube formation and also inhib-
ited hypotensive effect of S1P in rats (140), and an FTY720 
derivative 1-(hydroxymethyl)-3-(3-octylphenyl)cyclobutane 
(VPC03090), which show inhibition of tumor growth in vivo 
(141). An S1P derivative [N-((2S,3R)-3-hydroxy-1-morpholi-
no-4-(3-octylphenyl)butan-2-yl)tetradecanamide] (NHOBT) 
also shows inhibition of endothelial cell tube formation and 
endogenous neovascularization of the chick embryo cho-
rioallantoic membrane (142). It is expected that S1PR1/3 
antagonists with potent anti-angiogenic activity but relatively 
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weak inductive activities of vascular leak and eNOS inhibition 
would become promising therapeutics for controlling tumor 
angiogenesis. S1PR2 agonist, if developed, is also a promising 
candidate of anti-angiogenic medicine. 
Investigation in-depth into molecular mechanisms for S1P-
mediated regulation of angiogenesis, in combination with 
development of S1PR subtype-targeted, selective agonists 
and antagonists and their optimal drug delivery system, are 
expected to improve outcomes of both pro-angiogenic and 
anti-angiogenic therapies in the future. Their possible inter-
ference with biomolecules with angiogenic potentials, such 
as nerve growth factor (144-146) and leptin (147-149), might 
also be evaluated.
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